463 related articles for article (PubMed ID: 38449875)
1. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
Liu J; Zhang B; Zhang G; Shang D
Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review.
Wu X; Zhou Z; Cao Q; Chen Y; Gong J; Zhang Q; Qiang Y; Lu Y; Cao G
Front Immunol; 2023; 14():1268188. PubMed ID: 37753092
[TBL] [Abstract][Full Text] [Related]
3. Treg programming and therapeutic reprogramming in cancer.
Moreno Ayala MA; Li Z; DuPage M
Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting or reprogramming of intra-tumoral Tregs.
Mortezaee K
Med Oncol; 2024 Feb; 41(3):71. PubMed ID: 38341821
[TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
7. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
8. Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.
Munn DH; Sharma MD; Johnson TS
Cancer Res; 2018 Sep; 78(18):5191-5199. PubMed ID: 30181177
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
11. The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy.
Yan S; Zhang Y; Sun B
Sci China Life Sci; 2019 Feb; 62(2):179-186. PubMed ID: 30610537
[TBL] [Abstract][Full Text] [Related]
12. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
13. Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.
Riaz F; Huang Z; Pan F
Front Immunol; 2023; 14():1280741. PubMed ID: 37936703
[TBL] [Abstract][Full Text] [Related]
14. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
15. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.
Ma Y; Xu X; Wang H; Liu Y; Piao H
Front Immunol; 2023; 14():1228331. PubMed ID: 37671150
[TBL] [Abstract][Full Text] [Related]
16. Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.
Hosseinalizadeh H; Rabiee F; Eghbalifard N; Rajabi H; Klionsky DJ; Rezaee A
Front Med (Lausanne); 2023; 10():1244298. PubMed ID: 37828948
[TBL] [Abstract][Full Text] [Related]
17. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
18. Treg plasticity and human diseases.
Zhang Z; Guo J; Jia R
Inflamm Res; 2023 Dec; 72(12):2181-2197. PubMed ID: 37878023
[TBL] [Abstract][Full Text] [Related]
19. Modulating Treg stability to improve cancer immunotherapy.
Kang JH; Zappasodi R
Trends Cancer; 2023 Nov; 9(11):911-927. PubMed ID: 37598003
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
